Apollomics Announces Efficacy Of Vebreltinib In NSCLC Patients With MetEx14 Skipping Mutation Achieving An Overall Response Rate Of 75%
Portfolio Pulse from Benzinga Newsdesk
Apollomics Inc. (NASDAQ:APLM) announced the efficacy and safety data of vebreltinib from the KUNPENG clinical trial at the European Society of Medical Oncology Congress. The results show vebreltinib's potential as a new treatment for patients with cancers driven by MET alterations, particularly in Non-Small Cell Lung Cancer (NSCLC) with MetEx14 skipping mutation. The drug showed an overall response rate of 75% in patients with locally advanced or metastatic NSCLC harboring Exon-14 skipping mutations.
October 23, 2023 | 12:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Apollomics Inc.'s vebreltinib shows promising results in the KUNPENG clinical trial, potentially positioning the company as a leader in the treatment of cancers driven by MET alterations.
The positive results from the KUNPENG clinical trial of vebreltinib, a drug developed by Apollomics Inc., could potentially boost the company's reputation and market position in the field of cancer treatment. This could lead to increased investor interest and a potential rise in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100